All In Biotech

Drug Trial Radar · NCT05408221

the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma

Phase Ⅱ/III Studies to Investigate the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Mar 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 576 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

576

Planned (sponsor's estimate)

Start

Nov 11, 2022

Primary completion

Aug 1, 2025

Study completion Aug 1, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

There are two studies included in this protocol. One is an open-label Phase Ⅱ study . The other is a multi-center, double-blind, randomized, phase III study .

Conditions

  • Hepatocellular Carcinoma

Interventions

  • Rulonilimab+LenvatinibDrug

    Rulonilimab, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily

  • Rulonilimab placebo +LenvatinibDrug

    Rulonilimab placebo, intravenous (i.v.) administration every 3 weeks; Lenvatinib oral administration, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: From randomization to PR or CR.Up to approximately 35 months.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Huizhou Central People's Hospital

    Guandong, China · Recruiting

  • Jinan Central Hospital

    Shandong, China · Recruiting

  • Linyi Cancer Hospital

    Shandong, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

    Shenzhen, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.